“We are honoured and proud that these internationally leading researchers are taking an interest in Guard Therapeutics and the company’s drug development. The scientific committee’s combined expertise in our main focus area is considerable and will play an important role in the development of ROSgard specifically in cardiac surgery, both in the short and long term. A detailed review of the design of our clinical phase 2 study is currently underway. The study will include patients who are undergoing cardiac surgery and have additional risk factors for developing acute kidney injury in connection with this procedure,” Guard Therapeutics’ CEO, Tobias Agervald, says.

The members of the scientific committee will participate as independent researchers and do not represent their respective universities. The committee members are:

Prof. Dr. Alexander Zarbock, MD, Director and Chairman of the Department of Anesthesiology, Intensive Care and Pain Medicine at the University of Münster, Germany.

Prof. Dr. Andreas Böning, MD, Director of the Clinic for Cardiac, Congenital and Vascular Surgery at the University Hospital Giessen and Marburg, Germany, and Chairman of Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie.

Prof. Claudio Ronco, MD, Director of the Department of Nephrology Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV) and Professor of Nephrology at the Department of Medicine (DIMED) of the University of Padova, Italy.

Prof. Daniel Engelman, MD, Medical Director of Heart, Vascular and Critical Care Units at Baystate Medical Center, USA, President of the Massachusetts Society of Thoracic Surgeons (STS) and Professor of Surgery at the University of Massachusetts-Baystate.

Prof. Jay L Koyner, MD, Director of the Inpatient Dialysis Unit and ICU Nephrology at the University of Chicago Medical Center, USA and Professor at the Department of Internal Medicine at the University of Chicago, USA.